title: Pathogenesis of cardiac dysfunction during metabolic acidosis: therapeutic implications.
abstract: Based on work performed in many laboratories including our own, we suggest the following schematic shown in Figure 4 to explain metabolic acidosis and the effects of alkalinization therapy. Metabolic acidosis induces prompt and substantial decreases in cardiac functional performance. This is mediated by an intracellular acidosis which impairs cardiac function directly as well as leads to an impairment of cardiac energy metabolism which further impairs cardiac function. Attempts to alkalinize the cell with sodium bicarbonate therapy lead to a paradoxical intracellular acidosis and further impairment of cardiac function, whereas Carbicarb may correct the intracellular acidosis and improve physiological function. However, at the time which this paper was written, Carbicarb was not available for clinical use in the United States.
authors.affiliation: Giles Filley Research Laboratory, Webb Waring Institute for Biomedical Research, Denver, Colorado, USA. Joe.Shapiro@UCHSC.EDU
authors.forename: J I
authors.initials: JI
authors.lastname: Shapiro
mesh_terms: D000138:Acidosis / Q000178:diet therapy* / Q000503:physiopathology*; D000818:Animals; D002254:Carbonates / Q000627:therapeutic use; D004338:Drug Combinations; D004734:Energy Metabolism / Q000502:physiology; D006321:Heart / Q000503:physiopathology*; D006801:Humans; D017693:Sodium Bicarbonate / Q000627:therapeutic use
chemical_list: D002254:Carbonates; D004338:Drug Combinations; C046283:sodium bicarbonate, sodium carbonate drug combination; D017693:Sodium Bicarbonate